Sorafenib Tosylate Tablets
Formulation (FDF) · Tablets · 0.2g
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Sorafenib Tosylate Tablets
- Dosage Form
- Tablets
- Strength
- 0.2g
- Therapy Area
- Oncology
- Indication
- Renal cell carcinoma advanced; Hepatocellular carcinoma inoperable; Hepatocellular carcinoma metastatic
- Current Status
- Official FDF licensing catalog (UB308)
- GMP Certification
- CN - NMPA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3004.903 customs bills on file
Registrable Markets
China
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price